Prediction of long-term dependence on vitamin D analogues following total thyroidectomy for Graves' disease.
Calcium
Graves’ disease
Hypoparathyroidism
Parathyroid hormone
Total thyroidectomy
Journal
Annals of the Royal College of Surgeons of England
ISSN: 1478-7083
Titre abrégé: Ann R Coll Surg Engl
Pays: England
ID NLM: 7506860
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
pmc-release:
01
02
2024
pubmed:
22
4
2022
medline:
3
2
2023
entrez:
21
4
2022
Statut:
ppublish
Résumé
This study aimed to identify patients at risk of long-term hypocalcaemia following total thyroidectomy for Graves' disease, and to determine the thresholds of postoperative day 1 serum calcium and parathyroid hormone (PTH) at which long-term activated vitamin D treatment can be safely excluded. This study was a retrospective analysis of 115 consecutive patients undergoing total thyroidectomy for Graves' disease at a university referral centre between 2010 and 2018. Outcome measures were the day 1 postoperative adjusted calcium and PTH results, and vitamin D analogue need at 6 months postoperatively. Logistic receiver operating curves were used to identify optimal cut-off values for adjusted serum calcium and serum PTH, and sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated. Temporary hypocalcaemia was observed in 20.9% of patients (mean day 1 serum adjusted calcium 2.2±0.14mmol/l and PTH 4.15±2.42pmol/l). Long-term (>6 months) activated vitamin D analogue therapy was required in five patients (4.3%), four of whom had normal serum PTH and one with undetectable PTH at 6 weeks post surgery. No patient with a day 1 postoperative calcium >2.05mmol/l and detectable PTH required vitamin D supplementation at 6 months post surgery (100% sensitivity, PPV 50%, NPV 100%). The biochemical postoperative day 1 thresholds identified in this paper have a 100% NPV in the identification of patients who are likely to require either no or only temporary activated vitamin D supplementation. We were able to identify all patients requiring activated vitamin D supplementation 6 months postoperatively from the day 1 postoperative serum calcium and PTH values, while excluding those that may only need temporary calcium supplementation. These threshold levels could be used for targeted follow-up and management of this subset of patients most at risk of long-term hypocalcaemia.
Identifiants
pubmed: 35446722
doi: 10.1308/rcsann.2022.0007
pmc: PMC9889183
doi:
Substances chimiques
Calcium
SY7Q814VUP
Vitamin D
1406-16-2
Parathyroid Hormone
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
157-161Références
Br J Surg. 2014 Mar;101(4):307-20
pubmed: 24402815
J Am Coll Surg. 1994 Jan;178(1):11-6
pubmed: 8156110
Asian J Surg. 2007 Jul;30(3):178-82
pubmed: 17638636
World J Surg. 2006 Aug;30(8):1428-33
pubmed: 16871356
Br J Surg. 2015 Mar;102(4):359-67
pubmed: 25605285
Br J Surg. 2018 Sep;105(10):1313-1318
pubmed: 29663312
Int J Surg. 2019 Dec;72:156-165
pubmed: 31704426
Br J Surg. 2018 Mar;105(4):350-357
pubmed: 29405252
Surgery. 2015 Dec;158(6):1492-9
pubmed: 26144879
Open Med (Wars). 2019 Jun 07;14:437-442
pubmed: 31231683
JAMA. 2015 Dec 15;314(23):2544-54
pubmed: 26670972
Ann Surg. 2002 Nov;236(5):564-9
pubmed: 12409661
World J Surg. 2006 May;30(5):825-32
pubmed: 16680597
Ear Nose Throat J. 2010 Sep;89(9):462-5
pubmed: 20859873